$29.33
+2.9%STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Advisor
Compensation
$821,219
Chief Development Officer and Chief Clinical, Regulatory & Medical Affairs Officer
Compensation
$569,734
Chief Executive Officer & Director
Compensation
$115,000
Chief Marketing Officer
Chief Medical Officer
Compensation
$691,149
Interim Chief Financial Officer
Compensation
$755,300
President & Chief Operating Officer
Compensation
$595,869
Senior Vice President of Commercial Operations - North America & APAC
Compensation
$755,647
Senior Vice President, Chief Legal Officer, General Counsel & Corporate Secretary
Compensation
$486,974
Vice President of Investor Relations & Corporate Development
During the last 12 months, insiders have purchased $28.78M worth of STAA shares, with no selling activity reported.
316.0K
5.88M
0
0.00
+5.9M
+$5.88M
30.7K
677.22K
0
0.00
+677K
+$677K
797.5K
22.22M
0
0.00
+22.2M
+$22.22M
0
0.00
0
0.00
+0
+$0
Broadwood Partners, L.P.
Director, 10 Percent Owner:
$28.78M
No selling activity
Strong bullish signal with $28.78M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
STAA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 04, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | April 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 26, 2023 | April 26, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 24, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | June 08, 2020 | July 30, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 20, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2018 | June 14, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | May 01, 2017 | June 13, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.